文献速递肿瘤 PET/CT核素与放射性配体治疗

CXCR4靶向成像与内放射治疗在促结缔组织增生性小圆细胞肿瘤中的应用

CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors.
PubMed 文献 · J Nucl Med · 2023-06-22

在8例男性促结缔组织增生性小圆细胞肿瘤(DSRCT)患者中,[68Ga]pentixafor PET/CT的病灶摄取与[18F]FDG PET诊断效能相当,且与肿瘤细胞CXCR4免疫组化表达相符;4例终末期患者接受CXCR4靶向[90Y]内放射治疗,3例出现反应迹象,其中2例疾病稳定143天和176天,但骨髓抑制治疗范围内3例均需输血、2例发生发热性中性粒细胞减少(导致1例死亡)。

要点

  • [68Ga]pentixafor在全部DSRCT患者肿瘤病灶中显示摄取,诊断效能与[18F]FDG PET相当。
  • 4例终末期患者接受CXCR4靶向[90Y]内放射治疗,3例采用骨髓抑制剂量并自体干细胞移植。
  • 3例可评估患者均见反应迹象,2例疾病稳定143天和176天,1例尸检证实部分病理缓解。

核心结论

  • 研究验证CXCR4可作为DSRCT的诊断生物标志物和内放射治疗的有前景靶点,证明其可行性并首次提供临床疗效证据。

研究设计与样本

  • 8例男性DSRCT患者接受[18F]FDG与CXCR4靶向[68Ga]pentixafor双示踪剂PET/CT成像,并进行视觉比较和活性病灶摄取定量。
  • [68Ga]pentixafor摄取与肿瘤细胞免疫组化CXCR4表达进行相关性分析。
  • 4例终末期进展期患者接受CXCR4靶向[90Y]内放射治疗,报告安全性、RECIST 1.1缓解和生存。

主要发现

  • 全部DSRCT患者肿瘤病灶均显示[68Ga]pentixafor摄取,诊断效能与[18F]FDG PET相当。
  • 全部DSRCT活检经免疫组化证实相应CXCR4表达。
  • 4例接受CXCR4靶向[90Y]内放射治疗,其中3例采用骨髓抑制剂量范围并随后行自体干细胞移植。
  • 3例骨髓抑制剂量患者均需输血,2例发生发热性中性粒细胞减少(导致1例死亡),未出现严重非血液学不良事件。
  • 3例患者均观察到反应迹象,2例疾病分别稳定143天和176天,第3例尸检证实部分病理缓解。

关键数值与推荐

  • 未报告定量摄取阈值或CXCR4表达评分标准。

临床怎么用

  • 作者认为CXCR4是DSRCT的诊断生物标志物和内放射治疗的有前景靶点,并首次提供其临床疗效证据。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Desmoplastic small round cell tumor (DSRCT) is a rare, radiosensitive, yet difficult-to-treat sarcoma subtype affecting predominantly male adolescents. Extensive intraperitoneal seeding is common and requires multimodal management. With no standard therapy established, the prognosis remains poor, and new treatment options are needed. We demonstrate the clinical potential of C-X-C motif chemokine receptor 4 (CXCR4)-directed imaging and endoradiotherapy in DSRCT. Methods: Eight male patients underwent dual-tracer imaging with [18F]FDG and CXCR4-directed [68Ga]pentixafor PET/CT. A visual comparison of both tracers, along with uptake quantification in active DSRCT lesions, was performed. [68Ga]pentixafor uptake was correlated with immunohistochemical CXCR4 expression on tumor cells. Four patients with end-stage progressive disease underwent CXCR4-based endoradiotherapy. We report the safety, response by RECIST 1.1, and survival after endoradiotherapy. Results: Uptake of [68Ga]pentixafor in tumor lesions was demonstrated in all patients with DSRCT, providing diagnostic power comparable to [18F]FDG PET. Corresponding CXCR4 expression was confirmed by immunohistochemistry in all DSRCT biopsies. Finally, 4 patients were treated with CXCR4-directed [90Y]endoradiotherapy, 3 in a myeloablative dose range with subsequent autologous stem cell transplantation. All 3 required transfusions, and febrile neutropenia occurred in 2 patients (resulting in 1 death). Notably, severe nonhematologic adverse events were absent. We observed signs of response in all 3 patients, translating into disease stabilization in 2 patients for 143 and 176 d, respectively. In the third patient, postmortem autopsy confirmed a partial pathologic response. Conclusion: We validated CXCR4 as a diagnostic biomarker and a promising target for endoradiotherapy in DSRCT, demonstrated its feasibility, and provided the first evidence of its clinical efficacy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hartlapp I, Hartrampf PE, Serfling SE, et al. CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors. J Nucl Med. 2023. PMID: 37348915. doi:10.2967/jnumed.123.265464

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。